GlassScriptPhysician profile
Philippa Ehoro
NPI 1124409784
$2,936.86
in general payments reported to CMS, 2019-2025
19 companies · $635 in 2025
The $635 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $593 · 2023: $241 · 2024: $1,296 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $495.53 | 2024-2025 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $401.79 | 2024-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $249.85 | 2024-2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $244.59 | 2022 | |
| Axsome Therapeutics, INC. | $244.37 | 2025 | Auvelity |
| Si-Bone, INC. | $229.82 | 2022 | |
| Silk Road Medical, INC. | $142.90 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abiomed | $137.05 | 2023-2025 | Impella |
| Neurocrine Biosciences, INC. | $122.10 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $120.52 | 2024 | Fanapt |
| Edwards Lifesciences Corporation | $109.33 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lucid Diagnostics INC. | $102.14 | 2022 | |
| Acadia Pharmaceuticals INC | $97.44 | 2024 | Daybue |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.16 | 2021 | |
| Genentech USA, INC. | $71.38 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $38.55 | 2024 | |
| Pfizer INC. | $20.01 | 2021 | |
| Abbvie INC. | $16.21 | 2022 | |
| Glaxosmithkline, LLC. | $13.12 | 2023 | Bexsero, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippa Ehoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.